Repeated Measures and Longitudinal Data Analysis I

Levi Waldron

Welcome and outline - session 9

Learning objectives:

- Identify and define hierarchical and longitudinal data
- Analyze correlated data using Analysis of Variance
- Identify and define random and fixed effects

Textbook sections:

- Vittinghoff sections 7.1 (7.2-7.3 next class)

What are hierarchical and longitudinal data?

- Knee radiographs are taken yearly in order to understand the onset of osteoarthritis
- An indicator of heart damage is measured at 1, 3, and 6 days following a brain hemorrhage.
- Groups of patients in a urinary incontinence trial are assembled from different treatment centers
- Susceptibility to tuberculosis is measured in family members
- A study of the choice of type of surgery to treat a brain aneurysm either by clipping the base of the aneurysm or implanting a small coil. The study is conducted by measuring the type of surgery a patient receives from a number of surgeons at a number of different institutions.

What is the distinction between hierarchical and longitudinal data?

- Longitudinal data are repeated measures over time
- Longitudinal data are a type of hierarchical data
  - repeated measures are correlated, and nested within the observational unit (individual)
- Other non-longitudinal data can also be hierarchical

Definition: Hierarchical data are data (responses or predictors) collected from or specific to different levels within a study.

Important features of this type of data

1. The outcomes are correlated across observations
2. The predictor variables can be associated with different levels of a hierarchy. *e.g.* we might be interested in:
   - the volume of operations at the hospital,
   - whether it is a for-profit or not-for-profit hospital,
   - years of experience of the surgeon or where surgeons were trained,
   - how the choice of surgery type depends on the age and gender of the patient.

A Simple Repeated Measures Example: Fecal Fat

- Lack of digestive enzymes in the intestine can cause bowel absorption problems.
  - This will be indicated by excess fat in the feces.
  - Pancreatic enzyme supplements can alleviate the problem.
  - fecfat.csv: a study of fecal fat quantity (g/day) for individuals given each of a placebo and 3 types of pills

Table 7.1 Fecal fat (g/day) for six subjects

Subject number	Pill type				Subject Average
	None	Tablet	Capsule	Coated	
1	44.5	7.3	3.4	12.4	16.9
2	33.0	21.0	23.1	25.4	25.6
3	19.1	5.0	11.8	22.0	14.5
4	9.4	4.6	4.6	5.8	6.1
5	71.3	23.3	25.6	68.2	47.1
6	51.2	38.0	36.0	52.6	44.5
Pill type average	38.1	16.5	17.4	31.1	25.8

Option 1: non-hierarchical analysis (wrong)



Option 1: non-hierarchical analysis (wrong)

```
fit1way <- lm(fecfat ~ pilltype, data=fecfat)
```

	Df	Sum Sq	Mean Sq	F value	Pr(>F)
pilltype	3	2008.60	669.53	1.86	0.1687
Residuals	20	7193.36	359.67		

Table 1: One-way analysis of variance table for fecal fat dataset

- Does not account for similarity of measurements within individual
- Would be correct if each treatment were given to a different individual

Option 2: two-way analysis of variance (getting closer)

- Accounts for individual differences in mean fecal fat
- Fits a coefficient for mean fecal fat per indivudual





Option 2: 2-way analysis of variance (getting closer)

```
fit1way <- lm(fecfat ~ pilltype, data=fecfat)
```

	Df	Sum Sq	Mean Sq	F value	Pr(>F)
pilltype	3	2008.60	669.53	1.86	0.1687
Residuals	20	7193.36	359.67		

Table 2: One-way analysis of variance table for fecal fat dataset

```
fit2way <- lm(fecfat ~ subject + pilltype, data=fecfat)
```

	Df	Sum Sq	Mean Sq	F value	Pr(>F)
subject	5	5588.38	1117.68	10.45	0.0002
pilltype	3	2008.60	669.53	6.26	0.0057
Residuals	15	1604.98	107.00		

Table 3: Two-way analysis of variance table. Note the similarity of the pilltype row.

What happened??

- 1-way ANOVA correctly estimates the effect of pill type
- However, 1-way ANOVA fails to accommodate the correlation within subjects
- 1-way ANOVA over-estimates the residual variance
  - under-estimates the significance of pill type

Regression models for 1 and 2-way ANOVA

- Recall for ordinary multiple linear regression:

$$E[y|x] = \beta_0 + \beta_1 x_1 + \beta_2 x_2 + ... + \beta_p x_p$$

  - x_p are the predictors or independent variables
  - y is the outcome, response, or dependent variable
  - $E[y|x]$ is the expected value of y given x
  - β_p are the regression coefficients

Regression models for 1 and 2-way ANOVA

- One-way ANOVA (person i with pill type j):

$$\begin{aligned} FECFAT_{ij} &= \text{fecal fat measurement for person i with pill type j} \\ &= \mu + PILLTYPE_j + \epsilon_{ij} \end{aligned}$$

- Two-way ANOVA:

$$FECFAT_{ij} = \mu + SUBJECT_i + PILLTYPE_j + \epsilon_{ij}$$

Assumption: $\epsilon_{ij} \overset{iid}{\sim} N(0, \sigma^2_\epsilon)$

Correlations within subjects

- One-way ANOVA fails because it does not account for the correlation of measurements within-person
- How highly correlated are measurements on the same person? Consider subject i, pill types j and k:

$$corr(FECFAT_{ij}, FECFAT_{ik}) = \frac{cov(FECFAT_{ij}, FECFAT_{ik})}{sd(FECFAT_{ij})sd(FECFAT_{ik})}$$

- This is a measure of how large the subject effect is, in relation to the error term

Correlation within subjects

$$\begin{aligned} cov(FECFAT_{ij}, FECFAT_{ik}) &= cov(SUBJECT_i, SUBJECT_i) \\ &= var(SUBJECT_i) \\ &= \sigma^2_{subject}.(\text{definition}) \end{aligned}$$

- Equality 1:
  - μ and *pilltype* terms are assumed to be constant, so do not enter into covariance calculation
  - residuals ϵ are assumed to be independent
- Equality 2:
  - covariance with self is variance

Recall $SUBJECT_i$ is the term for individual in 2-way AOV. Now $\beta_i * subjectID$, will later be treated as a **random variable**

Correlation within subjects

Previous slide calculated *covariance*. Also need *variance*.

$$\begin{aligned} var(FECFAT_{ij}) &= var(SUBJECT_i, SUBJECT_i) + var(\epsilon_{ij}) \\ &= \sigma^2_{subject} + \sigma^2_{\epsilon}.(\text{definition}) \end{aligned}$$

- Difference is that the independent residuals do contribute to $var(FECFAT_{ij})$
- Variance is broken into componenets due to *subject* and *residual* variance

Intraclass Correlation

The correlation between two treatments j and k across subjects i is:

$$
\begin{aligned}
corr(FECFAT_{ij}, FECFAT_{ik}) &= \frac{cov(FECFAT_{ij}, FECFAT_{ik})}{sd(FECFAT_{ij})sd(FECFAT_{ik})} \\
&= \frac{\sigma^2_{subj}}{\sigma^2_{subj} + \sigma^2_{\epsilon}} \\
ICC &= \frac{\tau^2_{00}}{\tau^2_{00} + \sigma^2_{\epsilon}}
\end{aligned}
$$

Intuition behind correlations within subjects

Table 7.1 Fecal fat (g/day) for six subjects

Subject number	Pill type				Subject Average
	None	Tablet	Capsule	Coated	
1	44.5	7.3	3.4	12.4	16.9
2	33.0	21.0	23.1	25.4	25.6
3	19.1	5.0	11.8	22.0	14.5
4	9.4	4.6	4.6	5.8	6.1
5	71.3	23.3	25.6	68.2	47.1
6	51.2	38.0	36.0	52.6	44.5
Pill type average	38.1	16.5	17.4	31.1	25.8

Figure 2: Fecal Fat dataset

Variance of the subject averages (279.4) is increased by correlation of measurements within individual.

Calculation of correlations within subjects (ICC)

What is your estimate of the variability due to subjects, from the 2-way ANOVA?

```
sum(residuals(fit2way)^2) / 15 / 4 #df=15, divided by 4 pilltypes
```

```
## [1] 26.74972
```

```
279.419 - 26.75 #var(SUBJECT_i)
```

```
## [1] 252.669
```

Residual variance is:

```
sum(residuals(fit2way)^2) / 15 #df=15
```

```
## [1] 106.9989
```

Calculation of correlations within subjects (ICC)

Finally calculate ICC:

$$ICC = \frac{\sigma^2_{subj}}{\sigma^2_{subj} + \sigma^2_{\epsilon}}$$
$$= \frac{253}{253 + 107} \quad = 0.70$$

This calculation will become easier when we learn to estimate *random coefficients* in directly in the regression model.

The next step: a mixed effects model

- Two-way ANOVA is a fixed effects model:

$$FECFAT_{ij} = \beta_0 + \beta_{subjecti} SUBJECT_i + \beta_{pilltypej} PILLTYPE_j + \epsilon_{ij}$$

  - Assumption: $\epsilon_i \overset{iid}{\sim} N(0, \sigma^2_\epsilon)$

- Instead of fitting a $\beta_{subjecti}$ to each individual, assume that subject effects are selected from a distribution of possible subject effects:

$$FECFAT_{ij} = \mu + SUBJECT_i + \beta_{pilltypej} PILLTYPE_j + \epsilon_{ij}$$

  where $SUBJECT_i \overset{iid}{\sim} N(0, \sigma^2_{subj})$

- Here subject is a *random* effect, and pill type is a *fixed* effect.
- This is also a random intercept model

Random and fixed effects

Table 7.14 Decision tree for deciding between fixed and random



Figure 3: Random and Fixed Effects

Summary: correlations within subjects

- Subject-to-subject variability simultaneously raises or lowers all the observations on a subject
  - induces correlation of within-subject measurements
- Variability of individual measurements can be separated into that due to subjects and that left to residual variance.
  - $var(FECFAT_{ij}) = \sigma^2_{subj} + \sigma^2_{\epsilon}$
- 2-way ANOVA does not directly estimate variability due to subjects
  - variance of coefficients for individual is not too far off

Summary: hierarchical data

- Estimates of coeffients (or "effect sizes") are unchanged by hierarchical modeling
- Ignoring within-subject correlations results in incorrect estimates of variance, F statistics, p-values
  - not always "conservative"
- Intraclass Correlation (ICC) provides a measure of correlation induced by grouping
- Should be able to recognize fixed and random effects

Lab

1. Load the fecal fat dataset
2. Produce summary statistics for the dataset
3. Create a boxplot for fecal fat vs. treatment type
4. Create a spaghetti plots for fecal fat vs. treatment type, with and without subject means subtracted
5. Fit a linear model with random coefficients for pills, and summarize the output
6. Create residuals plots for this model and interpret
7. Calculate the ICC